ImmunoGen Future Growth
Future criteria checks 6/6
ImmunoGen is forecast to grow earnings and revenue by 45.2% and 26% per annum respectively. EPS is expected to grow by 44.6% per annum. Return on equity is forecast to be 33.2% in 3 years.
Key information
45.2%
Earnings growth rate
44.6%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 26.0% |
| Future return on equity | 33.2% |
| Analyst coverage | Good |
| Last updated | 12 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,026 | 389 | 280 | 341 | 7 |
| 12/31/2025 | 784 | 289 | 350 | 313 | 10 |
| 12/31/2024 | 541 | 109 | 175 | 148 | 10 |
| 12/31/2023 | 377 | 24 | 0 | 5 | 9 |
| 9/30/2023 | 288 | -74 | -200 | -198 | N/A |
| 6/30/2023 | 190 | -180 | -266 | -265 | N/A |
| 3/31/2023 | 121 | -240 | -263 | -262 | N/A |
| 12/31/2022 | 109 | -223 | -231 | -230 | N/A |
| 9/30/2022 | 96 | -201 | -217 | -215 | N/A |
| 6/30/2022 | 89 | -161 | -187 | -186 | N/A |
| 3/31/2022 | 92 | -129 | -167 | -166 | N/A |
| 12/31/2021 | 70 | -139 | -171 | -169 | N/A |
| 9/30/2021 | 128 | -71 | -116 | -115 | N/A |
| 6/30/2021 | 137 | -56 | -112 | -111 | N/A |
| 3/31/2021 | 135 | -49 | -97 | -95 | N/A |
| 12/31/2020 | 132 | -44 | -80 | -79 | N/A |
| 9/30/2020 | 91 | -71 | -121 | -120 | N/A |
| 6/30/2020 | 86 | -70 | -125 | -124 | N/A |
| 3/31/2020 | 87 | -89 | -128 | -127 | N/A |
| 12/31/2019 | 82 | -104 | -91 | -88 | N/A |
| 9/30/2019 | 51 | -151 | -101 | -97 | N/A |
| 6/30/2019 | 48 | -176 | -107 | -102 | N/A |
| 3/31/2019 | 42 | -174 | -113 | -106 | N/A |
| 12/31/2018 | 53 | -169 | -172 | -166 | N/A |
| 9/30/2018 | 79 | -140 | -159 | -155 | N/A |
| 6/30/2018 | 77 | -150 | -71 | -69 | N/A |
| 3/31/2018 | 107 | -117 | -11 | -9 | N/A |
| 12/31/2017 | 115 | -96 | 7 | 8 | N/A |
| 9/30/2017 | 90 | -117 | 0 | 1 | N/A |
| 6/30/2017 | 89 | -105 | N/A | -93 | N/A |
| 3/31/2017 | 57 | -142 | N/A | -150 | N/A |
| 12/31/2016 | 49 | -157 | N/A | -143 | N/A |
| 9/30/2016 | 53 | -156 | N/A | -141 | N/A |
| 6/30/2016 | 60 | -145 | N/A | -124 | N/A |
| 3/31/2016 | 65 | -129 | N/A | -120 | N/A |
| 12/31/2015 | 57 | -119 | N/A | -86 | N/A |
| 9/30/2015 | 87 | -72 | N/A | -68 | N/A |
| 6/30/2015 | 86 | -61 | N/A | -55 | N/A |
| 3/31/2015 | 79 | -57 | N/A | -46 | N/A |
| 12/31/2014 | 74 | -73 | N/A | -66 | N/A |
| 9/30/2014 | 56 | -82 | N/A | -49 | N/A |
| 6/30/2014 | 60 | -71 | N/A | -54 | N/A |
| 3/31/2014 | 58 | -67 | N/A | -46 | N/A |
| 12/31/2013 | 76 | -31 | N/A | -39 | N/A |
| 9/30/2013 | 49 | -59 | N/A | -63 | N/A |
| 6/30/2013 | 36 | -73 | N/A | -60 | N/A |
| 3/31/2013 | 35 | -73 | N/A | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMGN * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.7%).
Earnings vs Market: IMGN * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMGN * is expected to become profitable in the next 3 years.
Revenue vs Market: IMGN *'s revenue (26% per year) is forecast to grow faster than the MX market (6.5% per year).
High Growth Revenue: IMGN *'s revenue (26% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMGN *'s Return on Equity is forecast to be high in 3 years time (33.2%)